Indaptus Therapeutics, Inc. (INDP)

The immediate outlook is severely clouded by a collapse in share price and a complete lack of earnings power. While the stock recently spiked nearly 54% on speculation regarding financing or strategic options, the underlying reality is stark: the company has lost 99.95% of its value over the last nine years, with the trailing twelve-month EPS sitting at a deep loss of $3.56. The balance sheet shows massive negative free cash flow and negative operating cash flow, indicating the business is burning capital without generating returns. Although the current ratio is inflated at 19.48, this likely reflects minimal equity rather than robust liquidity, given the book value is a mere $0.011 per share. With no dividend history and a forward P/E that is mathematically impossible due to negative earnings, there is no safety margin here. The recent price surge appears to be a speculative event driven by uncertainty rather than a turnaround in fundamentals, leaving the security with a strong bearish signal for the near term and a definitive 'avoid' status for the long term.